Myriad RBM

Myriad RBM Addresses Complex Drug Development Challenges with Innovative Biomarker Services and the Novel Whole Blood Immunophenotyping Analyzer (TruCulture®). The Immunoassay Kits Developed and Manufactured In-House by Myriad RBM, Based on Multi-Analyte Profiling (MAP) and Ultra-Sensitive Single Molecule Array (SimoaTM) Technologies, Provide Clinical Researchers with Quantitative Data on Hundreds of Human Proteins. The Company Is a Wholly Owned Subsidiary of Myriad Genetics, Inc. (MYGN).